Serial No.: 09/700,293 Docket No.: BM45321

## In the Claims:

Claims 1-59 (Cancelled)

## BEST AVAILABLE COPY

- 60. (Currently Amended): An isolated polypeptide comprising a member selected from the group consisting of
  - (a) the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4;
  - (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 contiguous amino acids that matches an aligned contiguous segment of SEQ ID NO:2 or SEQ ID NO:4;

wherein the <u>immunogenic fragment</u> isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell <u>mediated</u> immune response <u>that recognizes the isolated</u> to a polypeptide having the sequence of SEQ ID NO:2 or SEQ ID NO:4.

- 61. (Previously Presented): The isolated polypeptide of claim 60, wherein the polypeptide is according to (a).
- 62. (Previously Presented): The isolated polypeptide of claim 60, wherein the polypeptide is according to (b).
- 63. (Currently Amended): The isolated polypeptide of claim 60, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.
- 64. (Previously Presented): The isolated polypeptide of claim 60, wherein the isolated polypeptide consists of SEQ ID NO:2 or SEQ ID NO:4.

BEST AVAILABLE COPY

Serial No.: 09/700,293 Docket No.: BM45321

65. (Previously Presented): A fusion protein comprising the isolated polypeptide of Claim

60.

66. (Previously Presented): An immunogenic composition comprising the polypeptide of Claim 60 and a pharmaceutically acceptable carrier.

- 67. (Previously Presented): The immunogenic composition of Claim 66, wherein the immunogenic composition further comprises at least one other *Neisseria Meningitidis* antigen.
- 68. (New): The isolated polypeptide of Claim 60, wherein the isolated polypeptide is a recombinant polypeptide.
- 69. (New): The isolated polypeptide of Claim 61, wherein the isolated polypeptide is a recombinant polypeptide.
- 70. (New): The isolated polypeptide of Claim 62, wherein the isolated polypeptide is a recombinant polypeptide.
- 71. (New): An immunogenic composition comprising the isolated polypeptide of claim 61.
- 72. (New): An immunogenic composition comprising the isolated polypeptide of claim 62.
- 73. (New): A fusion protein comprising the isolated polypeptide of claim 61.
- 74. (New): A fusion protein comprising the isolated polypeptide of claim 62.